The coinhibitory receptor PD-1 is an important target of immunotherapy now used in the clinic, yet exactly how PD-1 inhibits T cell function remains unclear. In Science, Kamphorst et al. and Hui et al. identify the T cell costimulatory receptor CD28 as the relevant target of PD-1-mediated inhibition. The former study shows that CD28 costimulation is required for CD8+ T cell proliferation after PD-1 blockade in mice, using chronic viral infection and tumor models. Preferential proliferation of CD28+ T cells is also seen in patients receiving anti-PD-1 therapies. Hui et al. show that PD-1 is phosphorylated by the kinase Lck upon PD-L1 ligation. This interaction brings PD-1 and CD28 into proximity. Phosphorylated PD-1 specifically recruits the phosphatase Shp2, which then dephosphorylates CD28 to terminate its signaling cascade and thereby inhibit T cell proliferation. These findings lend insights into how costimulatory molecules can be manipulated to enhance or inhibit adaptive immunity.
Rights and permissions
About this article
Cite this article
Dempsey, L. PD-1 targets CD28. Nat Immunol 18, 487 (2017). https://doi.org/10.1038/ni.3739
Published:
Issue Date:
DOI: https://doi.org/10.1038/ni.3739